No one who owned this stock would be getting out at cash value just when they are setting up to comercialize their technology with medicare coverage in place. Such a skeptic would never have owned the stock. Hence, the likely strategy at play is to have one entity hold the stock down and repress rallies while a partnered entity accumulates. This will shake a few shares out making the strategy pay off in the long term. This stategy is not idiotic, is quite commonly practiced in low volume stocks, disfavored companies with high potential up side.
well...that is the attitude that is encouraged while smart investors are slowly accumulating at this cash-basis valuation level, but once micro RNA becomes the gold standard of technology in the diagnostic sector, it will then be a question of only when the same thing will happen in the clinical treatment sector, and ROSG will be a billion dollar company.